The 36-month beta value for INSM is at 1.07. Analysts have varying views on the stock, with 12 analysts rating it as a “buy,” 6 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for INSM is 176.82M, and currently, shorts hold a 8.18% of that float. The average trading volume for INSM on March 27, 2025 was 1.81M shares.
INSM) stock’s latest price update
Insmed Inc (NASDAQ: INSM)’s stock price has plunge by -2.51relation to previous closing price of 78.54. Nevertheless, the company has seen a -3.00% plunge in its stock price over the last five trading sessions. prnewswire.com reported 2025-03-25 that —New Analyses from the Phase 3 ASPEN Study Examining Efficacy and Safety of Brensocatib Across a Variety of Prespecified Subgroups— —Data from ASPEN Post-hoc Analysis Evaluating Changes in Lung Function in Bronchiectasis Patients Who Did or Did Not Experience Pulmonary Exacerbations in the Trial— — Data on Health Status Improvements Over Time Following Culture Conversion in Patients with Mycobacterium Avium Complex (MAC) Lung Disease— BRIDGEWATER, N.J., March 25, 2025 /PRNewswire/ — Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will present 11 abstracts from across its respiratory portfolio at the American Thoracic Society (ATS) 2025 International Conference, taking place May 18-21, 2025, in San Francisco.
INSM’s Market Performance
Insmed Inc (INSM) has seen a -3.00% fall in stock performance for the week, with a -1.20% decline in the past month and a 8.70% surge in the past quarter. The volatility ratio for the week is 3.56%, and the volatility levels for the past 30 days are at 3.74% for INSM. The simple moving average for the past 20 days is -0.61% for INSM’s stock, with a 4.46% simple moving average for the past 200 days.
Analysts’ Opinion of INSM
Many brokerage firms have already submitted their reports for INSM stocks, with RBC Capital Mkts repeating the rating for INSM by listing it as a “Outperform.” The predicted price for INSM in the upcoming period, according to RBC Capital Mkts is $100 based on the research report published on February 25, 2025 of the current year 2025.
Truist, on the other hand, stated in their research note that they expect to see INSM reach a price target of $48. The rating they have provided for INSM stocks is “Buy” according to the report published on April 23rd, 2024.
Wolfe Research gave a rating of “Outperform” to INSM, setting the target price at $42 in the report published on February 15th of the previous year.
INSM Trading at -1.46% from the 50-Day Moving Average
After a stumble in the market that brought INSM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.82% of loss for the given period.
Volatility was left at 3.74%, however, over the last 30 days, the volatility rate increased by 3.56%, as shares sank -1.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.08% upper at present.
During the last 5 trading sessions, INSM fell by -3.00%, which changed the moving average for the period of 200-days by +33.93% in comparison to the 20-day moving average, which settled at $77.04. In addition, Insmed Inc saw 10.91% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at INSM starting from Lewis William, who sale 18,750 shares at the price of $77.03 back on Mar 17 ’25. After this action, Lewis William now owns 334,186 shares of Insmed Inc, valued at $1,444,241 using the latest closing price.
Lewis William, the Chair and CEO of Insmed Inc, sale 6,830 shares at $77.04 during a trade that took place back on Mar 17 ’25, which means that Lewis William is holding 233,924 shares at $526,179 based on the most recent closing price.
Stock Fundamentals for INSM
Current profitability levels for the company are sitting at:
- -2.2 for the present operating margin
- 0.76 for the gross margin
The net margin for Insmed Inc stands at -2.51. The total capital return value is set at -0.46. Equity return is now at value -890.75, with -54.47 for asset returns.
Based on Insmed Inc (INSM), the company’s capital structure generated 0.14 points at debt to capital in total, while cash flow to debt ratio is standing at -15.03. The debt to equity ratio resting at 0.16. The interest coverage ratio of the stock is -9.97.
Currently, EBITDA for the company is -818.79 million with net debt to EBITDA at 0.6. When we switch over and look at the enterprise to sales, we see a ratio of 36.7. The receivables turnover for the company is 6.99for trailing twelve months and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.45.
Conclusion
In conclusion, Insmed Inc (INSM) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
